{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:10:24Z","timestamp":1791216624088,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.cgh.2007.12.015","type":"journal-article","created":{"date-parts":[[2008,2,2]],"date-time":"2008-02-02T07:50:36Z","timestamp":1201938636000},"page":"545-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":179,"title":["Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"6","author":[{"given":"Viola","family":"Andresen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Montori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin P.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Layer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Camilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2007.12.015_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0016-5085(82)80186-8","article-title":"Bowel patterns among subjects not seeking health care","volume":"83","author":"Drossman","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2007.12.015_bib2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0016-5085(91)90717-Y","article-title":"Epidemiology of colonic symptoms and the irritable bowel syndrome","volume":"101","author":"Talley","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2007.12.015_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/bmj.304.6819.87","article-title":"Irritable bowel syndrome in the general population","volume":"304","author":"Jones","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2007.12.015_bib4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/BF01303162","article-title":"U.S. householder survey of functional gastrointestinal disorders","volume":"38","author":"Drossman","year":"1993","journal-title":"Dig Dis Sci"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2007.12.015_bib5","first-page":"II43","article-title":"Functional bowel disorders and functional abdominal pain","volume":"45","author":"Thompson","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2007.12.015_bib6","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/gast.1996.v111.pm8898642","article-title":"Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine","volume":"111","author":"Foxx-Orenstein","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2007.12.015_bib7","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1111\/j.1572-0241.2000.03177.x","article-title":"Serotonin: a mediator of the brain-gut connection","volume":"95","author":"Kim","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.12.015_bib8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1476-5381.1990.tb15836.x","article-title":"The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension","volume":"100","author":"Moss","year":"1990","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cgh.2007.12.015_bib9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1476-5381.1995.tb13263.x","article-title":"Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity","volume":"114","author":"Banner","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cgh.2007.12.015_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1023\/A:1026633629141","article-title":"Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist","volume":"44","author":"Miura","year":"1999","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2007.12.015_bib11","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/gut.46.4.474","article-title":"The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat","volume":"46","author":"Kozlowski","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2007.12.015_bib12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-2036.1998.00375.x","article-title":"Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome","volume":"12","author":"Delvaux","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2007.12.015_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2036.2002.01144.x","article-title":"Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans","volume":"16","author":"Kuo","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2007.12.015_bib14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2036.2000.00762.x","article-title":"Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers","volume":"14","author":"Houghton","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2007.12.015_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1365-2125.2000.00180.x","article-title":"Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial","volume":"49","author":"Stacher","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2007.12.015_bib16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/13543784.9.1.147","article-title":"Pharmacology and clinical experience with alosetron","volume":"9","author":"Camilleri","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cgh.2007.12.015_bib17","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/j.1572-0241.2001.04128.x","article-title":"Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome","volume":"96","author":"Lembo","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.12.015_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1572-0241.2001.03525.x","article-title":"Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome","volume":"96","author":"Watson","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.12.015_bib19","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.1999.00610.x","article-title":"Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist","volume":"13","author":"Camilleri","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2007.12.015_bib20","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1046\/j.1365-2036.1999.00678.x","article-title":"Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients","volume":"13","author":"Jones","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2007.12.015_bib21","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-200410001-00846","article-title":"Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 3-month US study","volume":"99","author":"Miner","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.12.015_bib22","first-page":"A-42","article-title":"Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 months global study","volume":"126","author":"Bradette","year":"2004","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2007.12.015_bib23","first-page":"II69","article-title":"Design of treatment trials for functional gastrointestinal disorders","volume":"45","author":"Veldhuyzen van Zanten","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2007.12.015_bib24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cgh.2007.03.004","article-title":"Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints","volume":"5","author":"Camilleri","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2007.12.015_bib25","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1111\/j.1572-0241.2002.07111.x","article-title":"Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome","volume":"97","author":"Olden","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.12.015_bib26","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/j.1572-0241.2001.04138.x","article-title":"Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome","volume":"96","author":"Viramontes","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.12.015_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2982.2003.00389.x","article-title":"Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials","volume":"15","author":"Cremonini","year":"2003","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2007.12.015_bib28","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2007.12.015_bib29","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","article-title":"Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial","volume":"355","author":"Camilleri","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2007.12.015_bib30","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","article-title":"A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome","volume":"161","author":"Camilleri","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2007.12.015_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2036.2000.00684.x","article-title":"A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome","volume":"14","author":"Bardhan","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2007.12.015_bib32","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S1542-3565(04)00284-8","article-title":"Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials","volume":"2","author":"Lembo","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2007.12.015_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials","volume":"323","author":"Juni","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2007.12.015_bib34","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1572-0241.2004.30509.x","article-title":"Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome","volume":"99","author":"Chey","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.12.015_bib35","first-page":"A-320","article-title":"Safety and efficacy of 0.5 mg qd, 1 mg qd, and 1 mg bid alosetron hydrochloride in women with chronic, severe diarrhea-predominant IBS (IBS-D)","volume":"130","author":"Krause","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2007.12.015_bib36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2007.12.015_bib37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2007.12.015_bib38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1572-0241.2005.40365.x","article-title":"A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS","volume":"100","author":"Chang","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.12.015_bib39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1572-0241.2001.03626.x","article-title":"Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients","volume":"96","author":"Wolfe","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.12.015_bib40","article-title":"Relief of symptoms in irritable bowel syndrome with diarrhea predominance (IBS-D) patients decreases after blinded withdrawal of cilansetron treatment","volume":"128","author":"Francisconi","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2007.12.015_bib41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","article-title":"The case of the misleading funnel plot","volume":"333","author":"Lau","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2007.12.015_bib42","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/jama.297.5.468-b","article-title":"Association between unreported outcomes and effect size estimates in Cochrane meta-analyses","volume":"297","author":"Furukawa","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2007.12.015_bib43","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1046\/j.1365-2036.2002.01287.x","article-title":"The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients","volume":"16","author":"Mayer","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2007.12.015_bib44","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-2036.1998.00375.x","article-title":"Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome","volume":"12","author":"Delvaux","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2007.12.015_bib45","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/00365529609006766","article-title":"A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome","volume":"31","author":"Efskind","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.12.015_bib46","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1572-0241.2006.00459.x","article-title":"Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data","volume":"101","author":"Chang","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.12.015_bib47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2982.2006.00861.x","article-title":"Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT(3) antagonist treatment?","volume":"19","author":"Camilleri","year":"2007","journal-title":"Neurogastroenterol Motil"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356507011573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356507011573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:02:19Z","timestamp":1761541339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356507011573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S1542356507011573"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2007.12.015","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2007.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}